Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how 91黑料 successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Select amongst our broad range of solutions and experience.
Driving payer education and awareness
91黑料 delivered a multifaceted omnichannel awareness campaign to provide a seamless customer experience between print and digital channels for a drug to treat PPD.
Rapid manuscript development and delivery
Through close collaboration with a client, the 91黑料 team provided the support necessary to advance a critical COVID-19 manuscript from outline through submission to acceptance in only 20 days.
PKU-specific HRQol Questionnaire Development & Validation
91黑料 developed the first PKU-specific Quality of Life questionnaire available and validated in four age groups and seven languages.
Retrospective Chart Review Study in Patients with Osteoporosis
This study was conducted to describe clinical characteristics and current treatment practices for patients with osteoporosis at high risk factor in Japan.
Leveraging Immuno-Oncology real world data
91黑料 supported a randomised phase 3 study to examine the study drug in combination with nivolumab vs chemotherapy in patients with checkpoint inhibitor refractory non-squamous NSCLC.
Successful adaptation to complex dose escalation
91黑料 was selected by a mid-size biotech company to support a phase 1 dose escalation and cohort expansion study of an immune checkpoint inhibitor, in patients with advanced solid tumors. Mid-study, the sponsor was acquired by a large pharma company to which 91黑料 has efficiently supported the transition to the evolving sponsor business model and operations.
Human Cytomegalovirus Vaccine Development
A pharmaceutical client needed to better understand patient perspectives, concerns and awareness of that could impact the development of a vaccine for Human Cytomegalovirus (HCMV).
H1N1 vaccine study
A sponsor approached 91黑料 during an influenza pandemic in Mexico to conduct a randomised, placebo controlled vaccine study with an investigative pandemic H1N1 vaccine.
Exceeding recruitment timelines
91黑料 was awarded a global study for Major Depressive Disease (MDD) in over 600 adult subjects. Enrollment began during the COVID pandemic and despite challenging protocol requirements, IMP expiry date and database lock requirements, 91黑料 reached LPR and DBL closed five months early.
Rapid mobilisation to advance COVID-19 vaccine development
COA Repository, revolutionizing the management of COAs within the sponsor’s clinical trials.
Successfully completing CGT study recruitment
91黑料 supported a phase 1/2/3, single-arm, open-label, multi-site, single dose in patients with transfusion-dependent ?-thalassemia. 91黑料 overcame patient recruitment challenges due to the complexity of the study and sites with limited experience with CRISPR-Cas9 modified gene therapy. All planned milestones were met, and first patient randomised was per plan.
.jpg?crop=yes&w=2000&h=1052&a=0,141&itok=MW8ABCQ6 "Doctor examining study participant"){kind=icon}
Phase 3 in primary immune thrombocytopenia
91黑料 was approached by a drug development sponsor to conduct a global, phase 3 trial in an adult patients with primary immune thrombocytopenia. The trial was part of a four-program study with challenging recruitment timelines.
Let's collaborate
Discover how 91黑料's expertise transforms clinical trials.